← Back to Clinical Trials
Recruiting NCT06467149

NCT06467149 Comparison of Frailty Screening Performance and Predictive Validity of Adverse Health Outcomes in Breast Cancer Patients Using Frailty Screening Tools

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06467149
Status Recruiting
Phase
Sponsor Ju Qiu
Condition Frailty Syndrome
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2023-08-12
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2023-08-12 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study uses the Physical Frailty Phenotype (PFP) as the diagnostic criterion for frailty and aims to explore the frailty screening scale FRAIL (The FRAIL Scale), Tilburg Frailty Index (TFI) and geriatric screening. Screening performance of Tool-8 (Geriatric-8, G-8) in breast cancer patients, to compare the predictive validity of different frailty screening scales for adverse health outcomes in breast cancer patients, and to select appropriate frailty screening methods for breast cancer patients in my country Screening scale.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of breast cancer * Age ≥50 years old * the treatment plan discussed by MDT includes surgery and chemotherapy * can walk on their own (with the assistance of walking aids) Exclusion Criteria: * Communication disorders * Mental disorders that can't cooperate normally * Combined with other malignant tumours * Terminal stage of the disease

Contact & Investigator

Central Contact

ju qiu, Bachelor.

✉ qiujuchongyi@163.com

📞 18523569369

Principal Investigator

Ling-Na kong

PRINCIPAL INVESTIGATOR

Tutor

Frequently Asked Questions

Who can join the NCT06467149 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Frailty Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06467149 currently recruiting?

Yes, NCT06467149 is actively recruiting participants. Contact the research team at qiujuchongyi@163.com for enrollment information.

Where is the NCT06467149 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT06467149 clinical trial?

NCT06467149 is sponsored by Ju Qiu. The principal investigator is Ling-Na kong at Tutor. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology